Pegmusirudin
Source Pegmusirudin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pegmusirudin is an experimental parenteral anticoagulant that belongs to the class of direct thrombin (factor IIa) inhibitors. It is mentioned in a 2011 review of new anticoagulants as a compound under development, intended for prevention or treatment of thromboembolic conditions. No regulatory status or clinical approval is reported in the cited literature.
Mechanism of Action
Pegmusirudin is described as a direct inhibitor of thrombin (factor IIa). By binding to the active site of thrombin, it blocks conversion of fibrinogen to fibrin and prevents platelet activation mediated by thrombin. This mechanism is similar to other recombinant hirudins, providing anticoagulation independent of antithrombin or heparin pathways.
What the Research Shows
The only source mentioning pegmusirudin is a 2011 review of emerging parenteral anticoagulants. The authors list pegmusirudin among several direct thrombin inhibitors (e.g., flovagatran, NU172) that are in pre‑clinical or early clinical development. No specific trial data, pharmacokinetic parameters, or efficacy outcomes are provided for pegmusirudin in the abstract. The review highlights the broader context of unmet needs with existing agents—such as renal clearance and lack of antidotes—but does not present detailed evidence for pegmusirudin itself.
Reported Benefits
Based on the review, pegmusirudin may offer the theoretical advantage of direct thrombin inhibition, potentially providing anticoagulation without reliance on antithrombin or heparin pathways. If developed, it could complement existing parenteral agents, especially in patients where current drugs have limitations (e.g., renal insufficiency, heparin‑induced thrombocytopenia). However, no empirical data are presented to substantiate these benefits.
Limitations of the Evidence
The literature provides only a brief mention of pegmusirudin, with no published clinical trial results, safety data, or dosing information. Consequently, its efficacy, optimal patient population, and comparative performance remain undefined. The lack of detailed pre‑clinical or clinical evidence limits any assessment of its therapeutic value at this stage.
Safety Considerations
No specific safety profile for pegmusirudin is reported in the cited source. As a direct thrombin inhibitor, general cautions applicable to this drug class would apply, including risk of bleeding and the need for monitoring anticoagulant effect. Without trial data, potential adverse events, contraindications, or availability of reversal agents cannot be described.
How It Is Administered
Pegmusirudin is classified as a parenteral anticoagulant, indicating it would be delivered by injection (intravenous or subcutaneous) rather than orally. The review does not specify formulation, dosage form, or administration schedule.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateGómez-Outes A, et al.2011-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of drug is pegmusirudin?
Pegmusirudin is an experimental direct thrombin (factor IIa) inhibitor being investigated as a parenteral anticoagulant.
Has pegmusirudin been approved for clinical use?
No. The available literature only mentions pegmusirudin as a compound under development; no regulatory approval or marketed status is reported.
How does pegmusirudin work?
It is described to bind directly to thrombin’s active site, blocking the conversion of fibrinogen to fibrin and reducing platelet activation, thereby providing anticoagulation.
Are there any clinical trial results for pegmusirudin?
The cited review does not provide specific trial data, efficacy outcomes, or safety information for pegmusirudin.
What are the potential risks of using pegmusirudin?
While no data are available for pegmusirudin itself, direct thrombin inhibitors generally carry a risk of bleeding, and careful monitoring would be expected if the drug were used clinically.
What is Pegmusirudin?
Pegmusirudin is an experimental parenteral anticoagulant that belongs to the class of direct thrombin (factor IIa) inhibitors. It is mentioned in a 2011 review of new anticoagulants as a compound under development, intended for prevention or treatment of thromboembolic conditions. No regulatory status or clinical approval is reported in the cited literature.